Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Relumina Non-Inferior to Leuprorelin in Japan PIII Study for Endometriosis: ASKA
ASKA Pharmaceutical said on March 15 that its gonadotropin-releasing hormone (GnRH) antagonist Relumina Tablets (relugolix) demonstrated non-inferiority to leuprorelin in a PIII comparative study conducted in 335 endometriosis patients with pelvic pain in Japan. In the study, patients received relugolix…
To read the full story
Related Article
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
BUSINESS
- Xospata Misses OS Endpoint in PIII Trial in Untreated FLT3-Mutated AML
March 10, 2026
- Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
March 10, 2026
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
- Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…